NCT02133612View on ClinicalTrials.gov

Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2014

Conditions
Esophageal Cancer
Interventions
DRUG

paclitaxel; cisplatin

The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.

Trial Locations (1)

100021

Xiao Lv, Beijing

All Listed Sponsors
lead

Chinese Academy of Medical Sciences

OTHER

NCT02133612 - Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter